Recent Advances in the Management of Patients with Advanced Hepatocellular Carcinoma: How Does Your Approach Compare with the Experts'?

TOOLKIT

Resources	Address
Abou-Alfa GK, et al. A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. *J Clin Oncol*. 2018;36(suppl; abstr TPS4144).	https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01789128/full
Abou-Alfa GK, et al. Cabozantinib in patients with advanced and progressing hepatocellular Carcinoma. *N Engl J Med.* 2018; 379(1):54-63.	https://www.nejm.org/doi/full/10.1056/nejmoa1717002
Abu-Sbeih H, et al. Clinically significant hepatotoxicity due to immune checkpoint inhibitors is rare but leads to treatment discontinuation in a high proportion. *Hepatology*. 2018;68(suppl 1):25A-26A.	https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.30256
American Cancer Society (ACS). Cancer Facts & Figures 2019.	https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf
Atezolizumab (Tecentriq®) PI 2020	https://www.gene.com/download/pdf/tecentriq_prescribing.pdf
Berhane S, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. *Clin Gastroenterol Hepatol*. 2016;14(6):875-886.e6.	https://pubmed.ncbi.nlm.nih.gov/26775025/
Bevacizumab (Avastin®) PI 2021.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s0169lbl.pdf
Brahmer JR, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 2018;36(17):1714-1768.	https://pubmed.ncbi.nlm.nih.gov/29442540/
Colevas AD, Setser A. The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials. *J Clin Oncol*. 2004;22(14 suppl):6098.	https://ascopubs.org/doi/abs/10.1200/jco.2004.22.90140.6098
CT/MRI LI-RADS v2018 CORE.	www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-2018-Core.pdf?la=en
De Martin E, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. *J Hepatol*. 2018;68(6):1181-1190.	https://pubmed.ncbi.nlm.nih.gov/29427729/
El-Khoueiry AB, et al. Impact of antitumor activity on survival outcomes, and nonconventi benefit, with nivolumab (NIVO)	https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.475

Resources	Address
in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040. *J Clin Oncol.* 2018;36(4_suppl):475-475.	
El-Khoueiry AB, et al. Nivolumab (NIVO) plus ipilimumab (IPI) combination thera patients (Pts) with advanced hepatocellular carcinoma (aH Long-term results from CheckMate 040. *J Clin Oncol.* 2021;39(3_suppl):269-269.	https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.269
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol.* 2018;69(1):182-236.	https://pubmed.ncbi.nlm.nih.gov/29628281/
Finn R, et al. IMbrave150: updated overall survival (OS) data from a global, randomized, open-label Phase III study of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). *Liver Cancer Summit.* 2021. Abstract 005.	https://easl.eu/wp-content/uploads/2021/01/Digital-Liver-Cancer-Summit-2021-Abstract-book.pdf
Finn RS, et al. Mbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC) *Cancer Res*. 2021;81(13_Suppl):Abstract nr CT009;	https://cancerres.aacrjournals.org/content/81/13_Supplement/CT009
Finn RS, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. *J Hepatol*. 2018;69(2):353-358. doi:10.1016/j.jhep.2018.04.010	https://pubmed.ncbi.nlm.nih.gov/29704513/
Finn RS, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med*. 2020;382(20):1894-1905.	https://www.nejm.org/doi/10.1056/NEJMoa1915745
Finn RS, et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label Phase III study of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). *J Clin Oncol.* 2021;39(3 suppl):267.	https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.267
Golfieri R, et al. Patients with Barcelona Clinic liver cancer stages B and C hepatocellular carcinoma: Time for a subclassification. *Liver Cancer*. 2019;8(2):78-91.	https://pubmed.ncbi.nlm.nih.gov/31019899/
Jennings JJ, et al. Hepatotoxicity induced by immune checkpoint inhibitors: A comprehensive review including current and alternative management strategies *Expert Opin Drug Metab Toxicol.* 2019;15(3):231-244.	https://www.tandfonline.com/doi/full/10.1080/17425255.2019.1574744
Kelley RK, et al. Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellula carcinoma (aHCC) who have not received previous systemic anticancer therapy. *J Clin Oncol.* 2019;37(15_suppl):TPS4157-TPS4157.	https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.TPS4157

Resources	Address
Kudo M, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet*. 2018;391(10126):1163-1173.	https://pubmed.ncbi.nlm.nih.gov/29433850/
Lenvatinib (Lenvima®) PI 2019.	www.lenvima.com/pdfs/prescribing-information.pdf
Li D, et al. Current treatment landscape for advanced hepatocellular carcinoma: Patient outcomes and the impact on quality of life. *Cancers (Basel)*. 2019;11(6):841.	https://pubmed.ncbi.nlm.nih.gov/31216701/
Llovet JM, t al. Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study. *J Clin Oncol.* 2019;37(15_suppl): TPS4152-TPS4152.	https://ascopubs.org/doi/abs/10.1200/jco.2019.37.15_suppl.tps4152
Llovet JM,. Molecular therapies and precision medicine for hepatocellular carcinoma. *Nat Rev Clin Oncol*. 2018;15(10):599-616.	https://www.nature.com/articles/s41571-018-0073-4?WT.feed_name=subjects_cancer-therapy
Llovet JM, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med*. 2008;359(4):378-390.	https://pubmed.ncbi.nlm.nih.gov/18650514/
Marrero JA, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. *Hepatology*. 2018;68(2):723-750.	https://pubmed.ncbi.nlm.nih.gov/29624699/
Michot JM, et al. Immune-related adverse events with immune checkpoint blockade: A comprehensive review. *Eur J Cancer*. 2016;54:139-148.	https://www.ejcancer.com/article/S0959-8049(15)01112-0/fulltext
Miller ED, et al. Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors. *Am J Gastroenterol.* 2020;115(2):251-261.	https://pubmed.ncbi.nlm.nih.gov/31789632/
National Comprehensive Cancer Network (NCCN). Hepatobiliary cancers. Version 4.2021. 8.26.2021.	www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf
Pugh RN, et al. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg*. 1973;60(8):646-649.	https://pubmed.ncbi.nlm.nih.gov/4541913/
Sangro B, et al. Nivolumab in sorafenib-naive and -experienced patients with advanced hepatocellular carcinoma (HCC): Survival, hepatic safety, and biomarker assessments in CheckMate 040. Presented at AASLD The Liver Meeting 2017. Abstract 141.	https://www.natap.org/2017/AASLD/AASLD_34.htm
Siegel RL, et al. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34.	https://pubmed.ncbi.nlm.nih.gov/30620402/

Resources	Address
Sorafenib (Nexavar®) PI 2018.	http://labeling.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf
Villanueva A. Hepatocellular carcinoma. *N Engl J Med*. 2019;380(15):1450-1462.	https://pubmed.ncbi.nlm.nih.gov/30970190/
Yau T, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial [published correction appears in JAMA Oncol. 2021 Jan 1;7(1):140]. *JAMA Oncol*. 2020;6(11):e204564. doi:10.1001/jamaoncol.2020.4564	https://pubmed.ncbi.nlm.nih.gov/33001135/
Yau T, et al. Nivolumab (NIVO) + ipilimumab (IPI) + caboza (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. *J Clin Oncol.* 2020;38(4_suppl):478-478.	https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.4_suppl.478
Zhu AX, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2019;20(2):282-296.	https://pubmed.ncbi.nlm.nih.gov/30665869/